About
Enjamb builds an agentic AI workspace that runs drug-development programs for biopharma teams, covering clinical evidence, trial design, statistical programming, and regulatory submissions. Its differentiation is a connection layer that operates on top of existing pharma systems and data without requiring migration, bringing execution across the full program into one platform.
Market
Enjamb competes in AI-native biopharma R&D, clinical-development, and regulatory-workflow software. It differentiates itself as a connection and execution layer that operates on top of systems such as Benchling, Veeva, Medidata, and SAS without requiring migration, while coordinating specialized agents across evidence, trial design, statistical programming, and submissions in one auditable workspace. Its competitive distinction is cross-functional program memory, parallel agent execution, source-backed outputs, and human review, versus broader clinical platforms and more specialized analytics or clinical-trial AI products.
Enjamb primarily targets biopharma and pharmaceutical R&D organizations running drug programs, with users and buyers across scientific research, clinical, biostatistics, and regulatory teams. Its positioning suggests a focus on established, cross-functional teams and research institutions rather than individual researchers, although the company does not publish a formal employee-size segment.
At a Glance
Problem
Enjamb addresses the operational bottleneck surrounding pharmaceutical R&D: drug programs can cost about $2.6 billion and take more than 10 years, while the evidence, documents, trials, statistical analyses, and regulatory work are scattered across closed systems such as Benchling, Veeva, Medidata, and SAS. These systems do not share context or provide an AI layer, so handoffs become fragmented, manual, and error-prone. The clearest high-value use case is regulatory submission preparation: Enjamb says it can generate an FDA submission package in 48 hours rather than eight months, with 23 times fewer errors than GPT-5.5.
Product / Service
Enjamb is an agentic AI workspace for biopharma teams. Its specialized agents operate on top of a company’s existing systems and data, without requiring migration, and coordinate work across clinical-evidence synthesis, trial design, statistical programming, regulatory drafting, and audit. The product is delivered through a browser-based workspace with document, spreadsheet, and presentation editors, Python and R computing, scientific integrations, and fine-tuned models for scientific validation.
The benefit is continuity and governance across the drug-development lifecycle: sources, files, code, tool calls, analyses, and decisions remain attached to outputs, while scientists, statisticians, clinical teams, and regulatory reviewers can inspect, redirect, and approve the agents’ work. Enjamb therefore positions itself as an execution and connection layer for existing pharma infrastructure rather than another disconnected summarization copilot.
Market
Enjamb competes in AI-enabled life-sciences R&D and biopharma workflow automation, particularly the emerging category of agentic platforms for drug development and regulatory operations. Its closest alternatives include the fragmented incumbent stack—Benchling, Veeva, Medidata, and SAS—which Enjamb connects to rather than replaces, as well as adjacent AI life-sciences platforms such as Causaly. It also competes against manual, handoff-heavy workflows and specialized point solutions for literature research, biostatistics, clinical trials, and regulatory-document automation.
The company appears to be an early-stage but already launched B2B SaaS business, not simply pre-product. Y Combinator lists it as an active Spring 2026 company, and Enjamb reports that within three weeks of launch its platform was being used by more than 500 employees at Johnson & Johnson, AbbVie, Bristol Myers Squibb, Merck, and Sanofi. It announced a $650,000 pre-seed backed by Y Combinator and Founders, Inc.; the cited materials do not disclose revenue or pricing, so commercial traction is clearer than its revenue status.
Founders & Leadership
Funding History
Y Combinator, Founders Inc.
Recent News
Enjamb launched on Y Combinator’s Launch YC as an agentic workspace connecting AI agents to existing biopharma systems, covering evidence synthesis, trial design, statistical programming, and regulatory submissions. The launch described 100+ scientific integrations and claimed adoption by employees at major pharmaceutical companies.
Enjamb announced a $650,000 pre-seed round backed by Y Combinator and Founders Inc. to develop its agentic research workspace for R&D teams. The company said researchers at more than 11 institutions were already using the platform and that the funding would support agent development and team growth.
Enjamb outlined its vision for an Integrated Research Environment: a shared workspace where researchers and AI agents collaborate across the full scientific lifecycle. The concept combines specialized agents, research editors and compute environments with direct connections to 60+ scientific databases.
Dealroom reported that Enjamb raised $650,000 in pre-seed funding from Y Combinator and Founders Inc. The coverage highlighted agents for literature reviews, methodology design, data analysis, grant discovery and manuscript drafting, along with reported use at more than 11 institutions.
Active Roles
0No active roles right now.
Get notified when they postBusiness Model
Enjamb monetizes through a freemium SaaS model: free access, paid individual Pro and Max plans, team-based Lab seats priced per user, and custom Enterprise contracts for pharma, biotech, and R&D organizations. Enterprise plans add unlimited usage, SSO/SAML, and dedicated support.